Why Is Ascendis Pharma A/S $ASND Stock Down -11.92% Today? (Find out why any stock moved today on Tickeron.) • $ASND shares fell 11.92% in Tuesday's session, dropping to about $233.34 from a prior close of $264.92. • The selloff followed a Raymond James downgrade from Strong Buy to Outperform, even as the firm kept its $287 price target. • The move was triggered by Ascendis' decision to regain full rights to its TransCon metabolic and cardiovascular programs from Novo Nordisk (NVO). • A newly authorized $400 million share repurchase program signaled management confidence but failed to offset investor concerns about a longer, less certain path to value. • Traders are now watching how the reclaimed obesity and cardiovascular pipeline develops and whether near-term commercial momentum holds. $APGE $ARGX $ACLX $MLYS $RYTM $PCVX $CRNX
published
Why Is Ascendis Pharma A/S $ASND Stock Down -11.92% Today? (Find out why any stock moved today on Tickeron.) • $ASND shares fell 11.92% in Tuesday's session, dropping to about $233.34 from a prior close of $264.92. • The selloff followed a Raymond James downgr
$ASND$APGE$ARGX$ACLX$MLYS$RYTM$PCVX$CRNX
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.
